References
- Anon. Orphan Drug Designations to June 30, 1991. Office of Orphan Products Development. July, 1991
- Telford R J, Hollway T E. The myasthenic syndrome: anaesthesia in a patient treated with 3,4 diaminopyridine. Br J Anaesth 1990; 64: 363–366
- Davis F A, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990; 27: 186–192
- Bever C T, Leslie J, Camenga D L, et al. Preliminary trial of 3,4 diaminopyridine in patients with multiple sclerosis. Ann Neurol 1990; 27: 421–427
- Stefoski D, Davis F A, Faut M, Schauf C L. 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1987; 21: 71–77
- van Diemen H A, Polman C H, van Dongen T M, et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neuro 1992; 32: 123–130
- Stefoski D, Davis F A, Fitzsimmons W E, et al. 4-aminopyridine in multiple sclerosis: prolonged administration. Neurology 1991; 41: 1344–1348
- van Diemen H A, van Dongen M M, Dammers J W, Polman C H. Increased visual impairment after exercise (Uhthoff's phenomenon) in multiple sclerosis: therapeutic possibilities. Eur Neurol 1992; 32: 231–234
- van Diemen H A, Polman C H, Koetsier J C, et al. 4-aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety. Clin Neuropharmacol 1993; 16: 195–204
- Kaji R, Sumner A J. Effects of 4-aminopyridine in experimental CNS demyelination. Neurology 1988; 38: 1884–1887
- Murray N M, Newsom Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 1981; 31: 265–271
- Wiseman E J, Jarvik L F. Potassium channel blockers: Could they work in alzheimer's disease?. Alzheimer's Dis Assoc Disord 1991; 5: 25–30
- Davis L E, Johnson J K, Bicknell J M, et al. Human type A botulism and treatment with 3,4 diaminopyridine. Electromyogr Clin Neurophysiol 1992; 32: 379–38
- Blight A R, Toombs J P, Bauer M S, Widmer W R. The effects of 4-aminopyridine on neurological deficits in chronic cases of traumatic spinal cord injury in dogs: a phase 1 clinical trial. J Neurotrauma 1991; 8: 103–119
- Palace J, Wiles C M, Newsom-Davis J. 3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia. J Neurol Neurosurg Psychiatry 1991; 54: 1069–1072
- McEvoy K M, Windebank A J, Daube J R, Low P A. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989; 321: 1567–1571
- Davidson M, Zemishlany Z, Mohs R C, et al. 4-Aminopyridine in the treatment of Alzheimer's disease. Biol Psychiatry 1988; 23: 485–490
- Blight A R. Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res Bull 1989; 22: 47–52
- Fossler M J, Leslie J, Burke M, et al. A reversed-phase ion-pair liquid chromatography method for the determination of 4-aminopyridine in Sprague-Dawley rats. J Phisiochemical Biomedical Analysis 1993; 6: 98–100
- Glover W E. The aminopyridines. Gen Pharmacol 1982; 13: 259–285
- Evenhuis J, Agoston S, Salt P J, et al. Pharmacokinetics of 4-aminopyridine in human volunteers. A preliminary study using a new GLC method for its estimation. Br J Anaesth 1981; 53: 567–570
- Ball A P, Hopkinson R B, Farrell I D, et al. Human botulism caused by Clostridium botulinum type E: the Birmingham outbreak. Q J Med 1979; 48: 473–491
- Blake K V, Massey K L, Hendeles L, et al. Relative efficacy of phenytoin and phenobarbital for the prevention of theophylline induced seizures in mice. Ann Emerg Med 1988; 17: 1024–1028
- Yamaguchi S, Rogawski M A. Effects of anticonvulsant drugs on 4-aminopyridine-induced seizures in mice. Epilepsy Res 1992; 11: 9–16